title: Acquired and intrinsic resistance in cancer immunotherapy.
abstract: A number of immunotherapies, in particular immune checkpoint targeting antibodies and adoptive T-cell therapies, are starting to transform the treatment of advanced cancers. The likelihood to respond to these immunotherapies differs strongly across tumor types, with response rates for checkpoint targeting being the highest in advanced melanoma, renal cell cancer and non-small cell lung cancer. However, also non-responsiveness is observed, indicating the presence of intrinsic resistance or naturally acquired resistance. In addition, a subgroup of patients that do initially respond to immunotherapy will later recur, thereby also pointing towards a role of therapy-induced acquired resistance. Here, we review our current understanding of both intrinsic and acquired resistance mechanisms in cancer immunotherapy, and discuss potential strategies to overcome them.
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
authors.forename: Sander
authors.initials: S
authors.lastname: Kelderman
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
authors.forename: Ton N M
authors.initials: TN
authors.lastname: Schumacher
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. Electronic address: j.haanen@nki.nl.
authors.forename: John B A G
authors.initials: JB
authors.lastname: Haanen
mesh_terms: D000818:Animals; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
keywords: Cancer immunotherapy; Immune resistance; T-cell response
references.citation: J Clin Invest. 2008 Apr;118(4):1398-404
references.pmid: 18317595
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846
references.citation: Blood. 1999 Mar 1;93(5):1634-42
references.pmid: 10029592
references.citation: Nat Immunol. 2002 Nov;3(11):999-1005
references.pmid: 12407407
references.citation: N Engl J Med. 2011 Aug 25;365(8):725-33
references.pmid: 21830940
references.citation: J Exp Med. 2004 Nov 15;200(10):1347-58
references.pmid: 15545358
references.citation: Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62
references.pmid: 8022805
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: Cancer Res. 2007 Nov 15;67(22):10669-76
references.pmid: 18006808
references.citation: N Engl J Med. 2003 Jan 16;348(3):203-13
references.pmid: 12529460
references.citation: Nat Immunol. 2002 Nov;3(11):991-8
references.pmid: 12407406
references.citation: J Immunother. 2004 May-Jun;27(3):184-90
references.pmid: 15076135
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: J Clin Oncol. 2011 Mar 1;29(7):917-24
references.pmid: 21282551
references.citation: Nature. 2012 Feb 08;482(7385):400-4
references.pmid: 22318521
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Mol Oncol. 2012 Apr;6(2):242-50
references.pmid: 22248437
references.citation: Sci Transl Med. 2011 Aug 10;3(95):95ra73
references.pmid: 21832238
references.citation: Gynecol Oncol. 2014 Mar;132(3):752-7
references.pmid: 24463159
references.citation: Cancer Immunol Immunother. 2013 Jun;62(6):1021-8
references.pmid: 23591982
references.citation: Cancer Res. 2009 Apr 1;69(7):3077-85
references.pmid: 19293190
references.citation: Sci Transl Med. 2012 Mar 28;4(127):127ra37
references.pmid: 22461641
references.citation: J Clin Oncol. 2013 Dec 1;31(34):4311-8
references.pmid: 24145345
references.citation: Clin Cancer Res. 2010 Dec 15;16(24):6122-31
references.pmid: 20668005
references.citation: Science. 2013 Mar 29;339(6127):1546-58
references.pmid: 23539594
references.citation: Cancer J. 2010 Jul-Aug;16(4):399-403
references.pmid: 20693853
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Breast Cancer Res Treat. 2011 May;127(1):99-108
references.pmid: 20556505
references.citation: Nature. 2012 Jan 26;483(7387):100-3
references.pmid: 22281684
references.citation: Gynecol Oncol. 2012 Feb;124(2):192-8
references.pmid: 22040834
references.citation: Science. 2008 Feb 22;319(5866):1096-100
references.pmid: 18202256
references.citation: EMBO J. 2013 Jan 23;32(2):194-203
references.pmid: 23258224
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2152-9
references.pmid: 23650429
references.citation: Cancer Res. 2012 Mar 1;72(5):1070-80
references.pmid: 22266112
references.citation: Clin Cancer Res. 2012 Dec 15;18(24):6758-70
references.pmid: 23032743
references.citation: J Clin Invest. 2014 May;124(5):2246-59
references.pmid: 24667641
references.citation: Annu Rev Immunol. 2013;31:51-72
references.pmid: 23157435
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Curr Opin Immunol. 2005 Oct;17(5):480-5
references.pmid: 16098721
references.citation: Science. 2014 May 9;344(6184):641-5
references.pmid: 24812403
references.citation: Blood. 2005 Oct 1;106(7):2375-81
references.pmid: 15947091
references.citation: Trends Immunol. 2002 Sep;23(9):445-9
references.pmid: 12200066
references.citation: Nat Med. 2013 Jun;19(6):747-52
references.pmid: 23644516
references.citation: Carcinogenesis. 2000 Mar;21(3):405-26
references.pmid: 10688861
references.citation: Cancer Res. 2008 Feb 1;68(3):889-92
references.pmid: 18245491
references.citation: Science. 2011 May 6;332(6030):687-96
references.pmid: 21551058
references.citation: J Pathol. 2014 Jan;232(2):199-209
references.pmid: 24122236
references.citation: Oncoimmunology. 2014 Jan 1;3(1):e27817
references.pmid: 24605269
references.citation: Clin Cancer Res. 2012 Apr 1;18(7):2039-47
references.pmid: 22271879
references.citation: J Clin Oncol. 2013 Nov 10;31(32):e439-42
references.pmid: 24043743
references.citation: Genome Res. 2014 May;24(5):743-50
references.pmid: 24782321
references.citation: Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
references.pmid: 22146893
references.citation: Curr Opin Immunol. 2013 Apr;25(2):284-90
references.pmid: 23566921
references.citation: Clin Cancer Res. 2011 Jul 1;17(13):4550-7
references.pmid: 21498393
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Int J Cancer. 2014 Jan 1;134(1):102-13
references.pmid: 23784959
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
references.pmid: 17671115
references.citation: J Immunol. 2004 Dec 15;173(12):7481-9
references.pmid: 15585874
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: J Clin Oncol. 2009 Dec 10;27(35):5944-51
references.pmid: 19858404
references.citation: Clin Cancer Res. 2013 Sep 1;19(17):4792-800
references.pmid: 23690483
references.citation: Cancer Res. 2001 Jul 1;61(13):5132-6
references.pmid: 11431351
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references.pmid: 22437870
references.citation: Nature. 2013 Aug 22;500(7463):415-21
references.pmid: 23945592
references.citation: Nat Med. 2007 Jan;13(1):84-8
references.pmid: 17159987
references.citation: Science. 2006 Oct 6;314(5796):126-9
references.pmid: 16946036
references.citation: Clin Cancer Res. 2014 Jan 1;20(1):44-55
references.pmid: 24045181
references.citation: Nature. 2014 Apr 3;508(7494):118-22
references.pmid: 24670642
references.citation: J Immunol. 1999 Apr 15;162(8):4567-75
references.pmid: 10201996
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: Nat Rev Cancer. 2013 Nov;13(11):788-99
references.pmid: 24132110
references.citation: J Natl Cancer Inst. 1996 Jan 17;88(2):100-8
references.pmid: 8537970
references.citation: N Engl J Med. 2013 Apr 18;368(16):1509-1518
references.pmid: 23527958
references.citation: J Exp Med. 1994 Jul 1;180(1):35-42
references.pmid: 8006593
references.citation: J Clin Invest. 2006 Sep;116(9):2423-33
references.pmid: 16955142
references.citation: Mol Oncol. 2014 Sep 12;8(6):1132-9
references.pmid: 25106088
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):253-68
references.pmid: 22437938
references.citation: Cancer. 1996 Apr 1;77(7):1303-10
references.pmid: 8608507